Skip to main content

Our Science

We explore the frontiers of science to further human health.

Our Technologies

Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.

Nrf2 Activators

nrf2 2flu

©Reata Pharmaceuticals, Inc.
Kelch domain of Keap1
PDB Code 2FLU

Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling (1-4). Omaveloxolone and Bardoxolone methyl are in development for the treatment of a severe neurological disorder called Friedreich’s ataxia and several forms of chronic kidney disease, respectively.

HSP90 Modulators

hsp90

©Reata Pharmaceuticals, Inc.
Middle segment of HSP90
PDB Code 1USV

We are developing a novel class of molecules that target pathways involved in the cellular stress response. Our lead product candidate, RTA 901, and related analogs have shown promising effects in animal models of neurological disease. RTA 901 is in development for Diabetic Peripheral Neuropathic Pain.

discover oval

Our Pipeline

Reata’s development programs have created a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases.

Phase 1
Phase 2
Pivotal
Regulatory Review
Neurology
Friedreich's Ataxia | Omaveloxolonea Friedreich's Ataxia
Omaveloxolone

The Phase 2 MOXIe Part 2 study was an international, multi-center, double-blind, placebo-controlled, randomized registrational study, that enrolled 103 patients with Friedreich’s ataxia (FA) at 11 study sites in the United States, Europe, and Australia and is the largest global, interventional study ever conducted in FA. Patients were randomized 1:1 to 150 mg of omaveloxolone or placebo. The primary endpoint was change in the modified Friedreich’s Ataxia Rating Scale (mFARS) relative to placebo after 48 weeks of treatment.

Follow the links to:

DPNPb | RTA 901 DPNP
RTA 901

We completed a Phase 1 SAD/MAD trial of oral, once-daily RTA 901 in healthy adult volunteers to evaluate the safety, tolerability, and PK profile. No safety or tolerability concerns were reported, and we observed an acceptable PK profile.

Follow the links to:

Chronic Kidney Disease
CKDc Caused by Alport Syndrome | Bardoxoloned CKD Caused by Alport Syndrome
Bardoxolone

The Phase 3 CARDINAL study was an international, multi-center, double-blind, placebo-controlled, randomized clinical trial that enrolled 157 patients with CKD caused by Alport syndrome at approximately 50 study sites in the United States, Europe, Japan, and Australia. Patients were randomized 1:1 to bardoxolone or placebo. The primary endpoint for Year 2 of the study was the change from baseline in eGFR after 100 weeks of treatment (end-of-treatment). The key secondary endpoint for Year 2 of the study was the change from baseline in eGFR at Week 104 (four weeks after last dose in second year of treatment).

Follow the links to:

CKD Caused by ADPKDe | Bardoxolone CKD Caused by ADPKD
Bardoxolone

FALCON is an international, multi-center, randomized, double-blind, placebo-controlled trial studying the safety and efficacy of bardoxolone in patients with ADPKD randomized one-to-one to active drug or placebo.

Follow the links to:

Type 1 and Type 2 Diabetes and Advanced CKD | Bardoxolonef Type 1 and Type 2 Diabetes
and Advanced CKD
Bardoxolone

AYAME is a randomized, double-blind, placebo-controlled, registrational outcomes trial of bardoxolone methyl in patients with diabetic CKD in Japan. The study enrolled approximately 1,000 Stage 3 and 4 diabetic kidney disease patients. The primary endpoint is the time to onset of at least a 30% decline in eGFR or end-stage kidney disease. AYAME is conducted by our strategic collaborator in Japan, Kyowa Kirin Co., Ltd.

Follow the links to:

aRolling New Drug Application submission completed in the first quarter of 2022. bDiabetic peripheral neuropathic pain (DPNP). cChronic Kidney Disease (CKD). dBardoxolone methyl (bardoxolone). On February 25, 2022, we received a Complete Response Letter from the Food and Drug Administration (FDA). We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. Marketing Authorisation Application in Europe is under review. eAutosomal Dominant Polycystic Kidney Disease (ADPKD). fAYAME study conducted in Japan by our strategic collaborator in CKD, Kyowa Kirin Co., Ltd.

Omaveloxolone, bardoxolone methyl, and RTA 901 are investigational drugs. Safety and efficacy have not been established by any agency.

References

References

  1. Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018) The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev 98, 1169-1203
  2. Hayes, J. D., and Dinkova-Kostova, A. T. (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci 39, 199-218
  3. Holmstrom, K. M., Kostov, R. V., and Dinkova-Kostova, A. T. (2016) The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol 1, 80-91
  4. Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., and Yamamoto, M. (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7, 11624
back to top
Palo Duro Canyon